As an age ≥1.5 years, INSS and MYCN amplification (MYCN-amp) are hazardous indicators in NB patients 2, 3, we analyzed ALKBH5 and FTO expression levels in different age, INSS and MYCN-amp groups and found that ALKBH5 levels were lower in the ≥1.5-year-old group, T3+T4 group and MYCN-amp groups (Figure 2A in upper panel). This evidence concerns the gene ALKBH5 and neuroblastoma.